MoneyWorks4Me

Lupin informs about press release

19 Feb 2021 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Lupin has informed that it has enclosed a Press Release on 19th February 2021 as regards receipt of USFDA approval for the Company's Droxidopa Capsules, 100 mg, 200 mg and 300 mg, to market a generic equivalent of Northera Capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..